Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Regorafenib in Advanced Biliary Tract Cancer
NCT05644392Phase 1Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cadonilimab in biliary tract cancer (BTC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Overall Response Rate at 1 year, Overall Survival at 3 years and 2 more. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05644392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644392.